Zoloft and Paranasal sinus hypersecretion - a phase IV clinical study of FDA data

Summary:

Paranasal sinus hypersecretion is reported as a side effect among people who take Zoloft (sertraline hydrochloride), especially for people who are female, 60+ old, also take Humira, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Paranasal sinus hypersecretion when taking Zoloft. It is created by eHealthMe based on reports of 128,159 people who have side effects when taking Zoloft from the FDA, and is updated regularly.

What is Zoloft?

Zoloft has active ingredients of sertraline hydrochloride. It is often used in depression. eHealthMe is studying from 138,801 Zoloft users. Check the latest studies of Zoloft.

What is Paranasal sinus hypersecretion?

Paranasal sinus hypersecretion is found to be associated with 436 drugs and 463 conditions by eHealthMe. Check the latest studies of Paranasal sinus hypersecretion.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

128,159 people reported to have side effects when taking Zoloft.
Among them, 31 people (0.02%) have Paranasal sinus hypersecretion.

Could Zoloft cause Paranasal sinus hypersecretion?

Among these 31 people:

What is the gender of people who have Paranasal sinus hypersecretion when taking Zoloft? *

female: 86.21 %
male: 13.79 %

What is the age of people who have Paranasal sinus hypersecretion when taking Zoloft? *

What are other drugs people take besides Zoloft? *

What are other side effects people have besides Paranasal sinus hypersecretion? *

Cough: 11 people, 35.48%
Malaise (a feeling of general discomfort or uneasiness): 8 people, 25.81%
Fatigue (feeling of tiredness): 7 people, 22.58%
Nausea (feeling of having an urge to vomit): 7 people, 22.58%
Chest Pain: 7 people, 22.58%
Dyspnea (difficult or laboured breathing): 6 people, 19.35%
Diarrhea: 6 people, 19.35%
Sinusitis (inflammation of sinus): 6 people, 19.35%
Fall: 5 people, 16.13%
Sinus Congestion (blockage of sinus): 5 people, 16.13%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 5 people, 16.13%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 4 people, 12.90%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 9.68%
High Blood Pressure: 3 people, 9.68%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 3 people, 9.68%
Migraine (headache): 3 people, 9.68%
Pain: 3 people, 9.68%
High Blood Cholesterol: 2 people, 6.45%
Nausea (feeling of having an urge to vomit): 2 people, 6.45%
Uterine Leiomyoma (uterine benign tumour derived from smooth muscle): 2 people, 6.45%

* Approximation only. Some reports may have incomplete information.

Do you take Zoloft and have Paranasal sinus hypersecretion?

- Check whether Paranasal sinus hypersecretion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zoloft:

Zoloft (138,801 reports)

Browse all side effects of Zoloft:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Paranasal sinus hypersecretion:

Paranasal sinus hypersecretion (436 drugs)

Browse all the conditions that are associated with Paranasal sinus hypersecretion:

Paranasal sinus hypersecretion (463 conditions)

Related publications that referenced our studies

Izgi C, Erdem G, Mansuroglu D, Kurtoglu N, Kara M, Gunesdogdu F, "Severe hypokalemia probably associated with sertraline use", Annals of Pharmacotherapy, 2014 Jan .
Izgi C, Erdem G, Mansuroglu D, Kurtoglu N, Kara M, Gunesdogdu F, "Severe hypokalemia probably associated with sertraline use", Annals of Pharmacotherapy, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on sertraline hydrochloride (the active ingredients of Zoloft) and Zoloft (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.